Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ZI-MA4-1a |
| Synonyms | |
| Therapy Description |
ZI-MA4-1a comprises allogeneic NK cells expressing an engineered TCR targeting an HLA-A*02:01-restricted MAGEA4 peptide and expressing a CD3 complex with a CD8 co-receptor, which potentially induces cytokine production and inhibits tumor growth (PMID: 41480010). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZI-MA4-1a | ZI-MA41a|ZI MA4-1a|ZIMA4-1a | ZI-MA4-1a comprises allogeneic NK cells expressing an engineered TCR targeting an HLA-A*02:01-restricted MAGEA4 peptide and expressing a CD3 complex with a CD8 co-receptor, which potentially induces cytokine production and inhibits tumor growth (PMID: 41480010). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07613723 | Phase I | Cyclophosphamide + Fludarabine ZI-MA4-1a | A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies | Recruiting | GBR | 0 |